Editorial: hepatitis C and porphyria cutanea tarda in 2020

Affiliations

Editorial

Sean Rudnick et al. Aliment Pharmacol Ther. 2020 Jun.

. 2020 Jun;51(12):1432-1434.

doi: 10.1111/apt.15728.

¹ Section on Gastroenterology & Hepatology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

No abstract available

Comment on

Resolution of subclinical porphyria cutanea tarda after hepatitis C eradication with direct-acting anti-virals.
Sastre L, To-Figueras J, Lens S, Rodriguez-Tajes S, Bartres C, Aguilera P, Badenas C, Oliva R, Pocurull A, Forns X, Mariño Z. Sastre L, et al. Aliment Pharmacol Ther. 2020 May;51(10):968-973. doi: 10.1111/apt.15703. Epub 2020 Apr 15. Aliment Pharmacol Ther. 2020. PMID: 32294804

1. Bonkovsky HL, Hou W, Li T, et al. Porphyrin and heme metabolism and the porphyrias. In: Wolkoff A, Lu S, Omary B, eds. Comprehensive Physiology. Bethesda, MD: The American Physiological Society, Wiley and Co;2013;365-401.
1. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. New Engl J Med. 2017;377:862-872.
1. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology. 1998;27:1661-1669.
1. Stölzel U, Köstler E, Schuppan D, et al. Hemochromatosis (HFE) gene mutations and response of chloroquine in porphyria cutanea tarda. Arch Dermatol. 2003;139:309-313.
1. Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multi-center, prospective, randomized, controlled trial. Hepatology. 2000;32:135-138.